{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:47:21Z","timestamp":1791902841707,"version":"4.3.4"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1132524"],"award-info":[{"award-number":["APP1132524"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1154692"],"award-info":[{"award-number":["APP1154692"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2008066"],"award-info":[{"award-number":["GNT2008066"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bmcl.2022.128837","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T11:31:24Z","timestamp":1653737484000},"page":"128837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Strategies for targeting the P2Y12 receptor in the central nervous system"],"prefix":"10.1016","volume":"71","author":[{"given":"Ben B.","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kassiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Danon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6817","key":"10.1016\/j.bmcl.2022.128837_b0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bmcl.2022.128837_b0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/glia.10293","article-title":"Selective Expression of Gi\/o-Coupled ATP Receptor P2Y12 in Microglia in Rat Brain","volume":"44","author":"Sasaki","year":"2003","journal-title":"Glia."},{"issue":"12","key":"10.1016\/j.bmcl.2022.128837_b0015","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/nn1805","article-title":"The P2Y12 receptor regulates microglial activation by extracellular nucleotides","volume":"9","author":"Haynes","year":"2006","journal-title":"Nat Neurosci."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128837_b0020","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3390\/ijms21041391","article-title":"P2y12 inhibition beyond thrombosis: Effects on inflammation","volume":"21","author":"Mansour","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128837_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-017-1034-z","article-title":"Purinergic receptors P2Y12R and P2X7R: Potential targets for PET imaging of microglia phenotypes in multiple sclerosis","volume":"14","author":"Beaino","year":"2017","journal-title":"J Neuroinflammation."},{"issue":"19","key":"10.1016\/j.bmcl.2022.128837_b0030","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.7150\/thno.25572","article-title":"Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state","volume":"8","author":"Villa","year":"2018","journal-title":"Theranostics."},{"issue":"3","key":"10.1016\/j.bmcl.2022.128837_b0035","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/cei.13649","article-title":"Towards PET imaging of the dynamic phenotypes of microglia","volume":"206","author":"Beaino","year":"2021","journal-title":"Clin Exp Immunol."},{"issue":"23","key":"10.1016\/j.bmcl.2022.128837_b0040","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/acschemneuro.1c00641","article-title":"Novel Thienopyrimidine-Based PET Tracers for P2Y12Receptor Imaging in the Brain","volume":"12","author":"van der Wildt","year":"2021","journal-title":"ACS Chem Neurosci."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128837_b0045","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1476-5381.2009.00596.x","article-title":"A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain","volume":"159","author":"And\u00f3","year":"2010","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.bmcl.2022.128837_b0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.nbd.2014.06.011","article-title":"Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents","volume":"70","author":"Horv\u00e1th","year":"2014","journal-title":"Neurobiol Dis."},{"key":"10.1016\/j.bmcl.2022.128837_b0055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbi.2015.11.007","article-title":"Microglial P2Y12 receptors regulate microglial activation and surveillance during neuropathic pain","volume":"55","author":"Gu","year":"2016","journal-title":"Brain Behav Immun."},{"issue":"12","key":"10.1016\/j.bmcl.2022.128837_b0060","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.bmcl.2016.04.030","article-title":"State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists","volume":"26","author":"Zetterberg","year":"2016","journal-title":"Bioorganic Med Chem Lett."},{"issue":"6","key":"10.1016\/j.bmcl.2022.128837_b0065","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1021\/acs.jmedchem.6b01620","article-title":"Design, Synthesis, and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer\u2019s Disease","volume":"60","author":"Bursavich","year":"2017","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128837_b0070","doi-asserted-by":"crossref","first-page":"114311","DOI":"10.1016\/j.bcp.2020.114311","article-title":"Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets","volume":"187","author":"Jacobson","year":"2021","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.bmcl.2022.128837_b0075","article-title":"PET Imaging of Neuroinflammation in Alzheimer\u2019s Disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.bmcl.2022.128837_b0080","doi-asserted-by":"crossref","unstructured":"Maeda J, Minamihisamatsu T, Shimojo M, et al. Distinct microglial response against Alzheimer\u2019s amyloid and tau pathologies characterized by P2Y12 receptor. Brain Commun. 2021;3(1). https:\/\/doi.org\/10.1093\/braincomms\/fcab011.","DOI":"10.1093\/braincomms\/fcab011"},{"issue":"5726","key":"10.1016\/j.bmcl.2022.128837_b0085","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.1110647","article-title":"Neuroscience: Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo","volume":"308","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bmcl.2022.128837_b0090","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","article-title":"Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases","volume":"53","author":"Tang","year":"2016","journal-title":"Mol Neurobiol."},{"key":"10.1016\/j.bmcl.2022.128837_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2013.12.010","article-title":"Dynamic structural remodelling of microglia in health and disease: A review of the models, the signals and the mechanisms","volume":"37","author":"Walker","year":"2014","journal-title":"Brain Behav Immun."},{"issue":"6","key":"10.1016\/j.bmcl.2022.128837_b0100","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/nn1472","article-title":"ATP mediates rapid microglial response to local brain injury in vivo","volume":"8","author":"Davalos","year":"2005","journal-title":"Nat Neurosci."},{"issue":"7","key":"10.1016\/j.bmcl.2022.128837_b0105","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nn.2341","article-title":"Adenosine A2A receptor mediates microglial process retraction","volume":"12","author":"Orr","year":"2009","journal-title":"Nat Neurosci."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128837_b0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrn3710","article-title":"Microglial phagocytosis of live neurons","volume":"15","author":"Brown","year":"2014","journal-title":"Nat Rev Neurosci."},{"issue":"3","key":"10.1016\/j.bmcl.2022.128837_b0115","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1038\/cddis.2013.54","article-title":"Minocycline selectively inhibits M1 polarization of microglia","volume":"4","author":"Kobayashi","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bmcl.2022.128837_b0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pneurobio.2016.04.006","article-title":"Microglial phenotypes in Parkinson\u2019s disease and animal models of the disease","volume":"155","author":"Joers","year":"2017","journal-title":"Prog Neurobiol."},{"issue":"12","key":"10.1016\/j.bmcl.2022.128837_b0125","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/glia.23484","article-title":"How to reprogram microglia toward beneficial functions","volume":"66","author":"Fumagalli","year":"2018","journal-title":"Glia."},{"key":"10.1016\/j.bmcl.2022.128837_b0130","doi-asserted-by":"crossref","first-page":"105290","DOI":"10.1016\/j.nbd.2021.105290","article-title":"Microglia reprogram metabolic profiles for phenotype and function changes in central nervous system","volume":"152","author":"Yang","year":"2021","journal-title":"Neurobiol Dis."},{"key":"10.1016\/j.bmcl.2022.128837_b0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bbi.2016.12.001","article-title":"Knockout of P2Y12 aggravates experimental autoimmune encephalomyelitis in mice via increasing of IL-23 production and Th17 cell differentiation by dendritic cells","volume":"62","author":"Zhang","year":"2017","journal-title":"Brain Behav Immun."},{"key":"10.1016\/j.bmcl.2022.128837_b0140","doi-asserted-by":"crossref","first-page":"106045","DOI":"10.1016\/j.phrs.2021.106045","article-title":"The dualistic role of the purinergic P2Y12-receptor in an in vivo model of Parkinson\u2019s disease: Signalling pathway and novel therapeutic targets","volume":"176","author":"Iring","year":"2022","journal-title":"Pharmacol Res."},{"issue":"17","key":"10.1016\/j.bmcl.2022.128837_b0145","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1021\/jm400820m","article-title":"Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y 12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283","volume":"56","author":"Bach","year":"2013","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128837_b0150","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejmech.2013.04.007","article-title":"Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor","volume":"65","author":"Bach","year":"2013","journal-title":"Eur J Med Chem."},{"issue":"6","key":"10.1016\/j.bmcl.2022.128837_b0155","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/jcbfm.2014.45","article-title":"Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor","volume":"34","author":"Gelosa","year":"2014","journal-title":"J Cereb Blood Flow Metab."},{"issue":"8","key":"10.1016\/j.bmcl.2022.128837_b0160","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10822-015-9858-z","article-title":"Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information","volume":"29","author":"Paoletta","year":"2015","journal-title":"J Comput Aided Mol Des."},{"issue":"22","key":"10.1016\/j.bmcl.2022.128837_b0165","doi-asserted-by":"crossref","first-page":"9981","DOI":"10.1021\/acs.jmedchem.5b01972","article-title":"Drug-like Antagonists of P2Y Receptors - From Lead Identification to Drug Development","volume":"59","author":"Conroy","year":"2016","journal-title":"J Med Chem."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128837_b0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.drudis.2018.09.021","article-title":"Antithrombotic P2Y 12 receptor antagonists: recent developments in drug discovery","volume":"24","author":"Baqi","year":"2019","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.bmcl.2022.128837_b0175","article-title":"Thieno[2,3-d]pyrimidine compounds","author":"Ennis","year":"2006","journal-title":"WO2006103544A2"},{"key":"10.1016\/j.bmcl.2022.128837_b0180","unstructured":"Lee C S, Lee T H, Yoon S K, et al. Lee C S, Lee T H, Yoon S K, et al. Fused Heterocyclic compound, \ufeffWO2010027236A2, 2010."},{"issue":"21","key":"10.1016\/j.bmcl.2022.128837_b0185","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1021\/acs.jmedchem.9b01220","article-title":"The Blood-Brain Barrier (BBB) Score","volume":"62","author":"Gupta","year":"2019","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128837_b0190","doi-asserted-by":"crossref","first-page":"104851","DOI":"10.1016\/j.compbiomed.2021.104851","article-title":"Na D. In silico methods and tools for drug discovery","volume":"137","author":"Shaker","year":"2021","journal-title":"Comput Biol Med."},{"key":"10.1016\/j.bmcl.2022.128837_b0195","doi-asserted-by":"crossref","first-page":"113705","DOI":"10.1016\/j.ejmech.2021.113705","article-title":"Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review","volume":"224","author":"Sabe","year":"2021","journal-title":"Eur J Med Chem."},{"issue":"21","key":"10.1016\/j.bmcl.2022.128837_b0200","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.2174\/0929867324666171107101035","article-title":"The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization","volume":"26","author":"Bruno","year":"2019","journal-title":"Curr Med Chem."},{"issue":"6","key":"10.1016\/j.bmcl.2022.128837_b0205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem Neurosci."},{"issue":"2","key":"10.1016\/j.bmcl.2022.128837_b0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128837_b0215","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-016-0016-2","article-title":"Strategies to facilitate the discovery of novel CNS PET ligands","volume":"1","author":"Zhang","year":"2017","journal-title":"EJNMMI Radiopharm Chem."},{"issue":"11","key":"10.1016\/j.bmcl.2022.128837_b0220","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1021\/jm400312y","article-title":"Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand","volume":"56","author":"Zhang","year":"2013","journal-title":"J Med Chem."},{"issue":"11","key":"10.1016\/j.bmcl.2022.128837_b0225","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1021\/jm201136z","article-title":"Structural modifications that alter the P-glycoprotein efflux properties of compounds","volume":"55","author":"Hitchcock","year":"2012","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128837_b0230","doi-asserted-by":"crossref","first-page":"113924","DOI":"10.1016\/j.ejmech.2021.113924","article-title":"P2Y12 antagonists: Approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies","volume":"227","author":"Al-Najjar","year":"2022","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128837_b0235","doi-asserted-by":"crossref","unstructured":"Koeppe R A, Frey K A, Snyder S E, Meyer P, Kilbourn M R, Kuhl D E. Kinetic Modeling of N-[ 11 CJMethylpiperidin-4-yl Propionate: Alternatives for Analysis of an Irreversible Positron Emission Tomography Tracer for Measurement of Acetylcholinesterase Activity in Human Brain. vol. 19. 1999.","DOI":"10.1097\/00004647-199910000-00012"},{"key":"10.1016\/j.bmcl.2022.128837_b0240","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-bioeng-062117-121056","article-title":"Human Positron Emission Tomography Neuroimaging","volume":"21","author":"Hooker","year":"2019","journal-title":"Annu Rev Biomed Eng."},{"issue":"7","key":"10.1016\/j.bmcl.2022.128837_b0245","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1538-7836.2007.02598.x","article-title":"The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel\u2019s active metabolite","volume":"5","author":"SUGIDACHI","year":"2007","journal-title":"J Thromb Haemost."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128837_b0250","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10822-011-9423-3","article-title":"Comparison of three GPCR structural templates for modeling of the P2Y 12 nucleotide receptor","volume":"25","author":"Deflorian","year":"2011","journal-title":"J Comput Aided Mol Des."},{"key":"10.1016\/j.bmcl.2022.128837_b0255","doi-asserted-by":"crossref","unstructured":"Yang Z, Zhang Y, Wang X, Qiao Y. Pharmacophore model generation of P2Y 12 inhibitor. Proc. - 2012 Int. Conf. Biomed. Eng. Biotechnol. iCBEB 2012. 2012;396\u20139. https:\/\/doi.org\/10.1109\/iCBEB.2012.293.","DOI":"10.1109\/iCBEB.2012.293"},{"issue":"7498","key":"10.1016\/j.bmcl.2022.128837_b0260","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature13083","article-title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"7498","key":"10.1016\/j.bmcl.2022.128837_b0265","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature13288","article-title":"Agonist-bound structure of the human P2Y12 receptor","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bmcl.2022.128837_b0270","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1080\/07391102.2016.1237381","article-title":"Investigating the binding mechanism of novel 6-aminonicotinate-based antagonists with P2Y12 by 3D-QSAR, docking and molecular dynamics simulations","volume":"35","author":"Zhou","year":"2017","journal-title":"J Biomol Struct Dyn."},{"issue":"6","key":"10.1016\/j.bmcl.2022.128837_b0275","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s00044-016-1557-3","article-title":"Features of reversible P2Y12 receptor antagonists based on piperazinyl-glutamate-pyridines","volume":"25","author":"Zhang","year":"2016","journal-title":"Med Chem Res."},{"issue":"3","key":"10.1016\/j.bmcl.2022.128837_b0280","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1139\/cjc-2014-0429","article-title":"A combination of pharmacophore modeling, molecular docking, and virtual screening for P2Y12 receptor antagonists from Chinese herbs","volume":"93","author":"He","year":"2015","journal-title":"Can J Chem."},{"issue":"10","key":"10.1016\/j.bmcl.2022.128837_b0285","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1021\/ci2002878","article-title":"Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines\/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation","volume":"51","author":"Hao","year":"2011","journal-title":"J Chem Inf Model."},{"issue":"24","key":"10.1016\/j.bmcl.2022.128837_b0290","doi-asserted-by":"crossref","first-page":"15752","DOI":"10.1021\/acs.jmedchem.0c01524","article-title":"Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y1and P2Y12as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor","volume":"63","author":"Lei","year":"2020","journal-title":"J Med Chem."},{"issue":"2","key":"10.1016\/j.bmcl.2022.128837_b0295","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1124\/jpet.109.156687","article-title":"Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor","volume":"331","author":"Hoffmann","year":"2009","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.bmcl.2022.128837_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.00093","article-title":"In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery","volume":"8","author":"de Souza Neto","year":"2020","journal-title":"Front Chem."},{"key":"10.1016\/j.bmcl.2022.128837_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmolb.2020.00001","article-title":"Application of Fragment-Based Drug Discovery to Versatile Targets","volume":"7","author":"Li","year":"2020","journal-title":"Front Mol Biosci."},{"key":"10.1016\/j.bmcl.2022.128837_b0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2018.00242","article-title":"An overview of in vitro methods to study microglia","volume":"12","author":"Timmerman","year":"2018","journal-title":"Front Cell Neurosci."},{"issue":"7","key":"10.1016\/j.bmcl.2022.128837_b0315","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3390\/molecules23071820","article-title":"Theoretical prediction of the complex P-glycoprotein substrate efflux based on the novel hierarchical support vector regression scheme","volume":"23","author":"Chen","year":"2018","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bmcl.2022.128837_b0320","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1021\/acs.molpharmaceut.8b01143","article-title":"Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models to Evaluate Transport Potential of P-Glycoprotein","volume":"16","author":"Ohashi","year":"2019","journal-title":"Mol Pharm."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128837_b0325","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1021\/acs.jmedchem.0c02011","article-title":"Development of an in Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration","volume":"64","author":"Watanabe","year":"2021","journal-title":"J Med Chem."},{"issue":"6","key":"10.1016\/j.bmcl.2022.128837_b0330","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.trechm.2019.04.009","article-title":"Challenges and Opportunities in Central Nervous System Drug Discovery","volume":"1","author":"Danon","year":"2019","journal-title":"Trends Chem."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128837_b0335","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jphs.2021.10.010","article-title":"Quantitative prediction of pharmacokinetic properties of drugs in humans: Recent advance in in vitro models to predict the impact of efflux transporters in the small intestine and blood\u2013brain barrier","volume":"148","author":"Hashimoto","year":"2022","journal-title":"J Pharmacol Sci."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128837_b0340","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph0135s71","article-title":"In Vitro Binding of [3H]PSB-0413 to P2Y12 Receptors","volume":"71","author":"Dupuis","year":"2015","journal-title":"Curr Protoc Pharmacol."},{"key":"10.1016\/j.bmcl.2022.128837_b0345","doi-asserted-by":"crossref","unstructured":"van Giezen J J J, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7(9):1556. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03527.x.","DOI":"10.1111\/j.1538-7836.2009.03527.x"},{"issue":"1","key":"10.1016\/j.bmcl.2022.128837_b0350","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11302-012-9329-0","article-title":"The platelet P2Y12 receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [3H]PSB-0413","volume":"9","author":"Ohlmann","year":"2013","journal-title":"Purinergic Signal."},{"issue":"21","key":"10.1016\/j.bmcl.2022.128837_b0355","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1016\/j.bmcl.2009.09.017","article-title":"Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation","volume":"19","author":"Parlow","year":"2009","journal-title":"Bioorganic Med Chem Lett."},{"issue":"16","key":"10.1016\/j.bmcl.2022.128837_b0360","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.bmcl.2009.06.075","article-title":"Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation","volume":"19","author":"Parlow","year":"2009","journal-title":"Bioorganic Med Chem Lett."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128837_b0365","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/jm901518t","article-title":"Piperazinyl glutamate pyridines as potent orally bioavailable P2Y 12 antagonists for inhibition of platelet aggregation","volume":"53","author":"Parlow","year":"2010","journal-title":"J Med Chem."},{"issue":"20","key":"10.1016\/j.bmcl.2022.128837_b0370","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1021\/jm300771j","article-title":"Identification of High-Affinity P2Y 12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone","volume":"55","author":"Zech","year":"2012","journal-title":"J Med Chem."},{"issue":"17","key":"10.1016\/j.bmcl.2022.128837_b0375","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/jm500588w","article-title":"N -[6-(4-Butanoyl-5-methyl-1 H -pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1 H -indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist","volume":"57","author":"Boldron","year":"2014","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128837_b0380","unstructured":"Kirk I. New Assay. \ufeffWO2000033080A2, 1999."},{"issue":"10","key":"10.1016\/j.bmcl.2022.128837_b0385","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.bmcl.2011.03.088","article-title":"A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor","volume":"21","author":"Bach","year":"2011","journal-title":"Bioorg Med Chem Lett."},{"issue":"13","key":"10.1016\/j.bmcl.2022.128837_b0390","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.bmcl.2014.04.001","article-title":"Optimization of ketone-based P2Y12 receptor antagonists as antithrombotic agents: Pharmacodynamics and receptor kinetics considerations","volume":"24","author":"Giordanetto","year":"2014","journal-title":"Bioorganic Med Chem Lett."},{"issue":"24","key":"10.1016\/j.bmcl.2022.128837_b0395","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1016\/j.bmcl.2005.08.104","article-title":"Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors","volume":"15","author":"El-Tayeb","year":"2005","journal-title":"Bioorganic Med Chem Lett."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:45:38Z","timestamp":1760773538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22003134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":79,"alternative-id":["S0960894X22003134"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128837","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for targeting the P2Y12 receptor in the central nervous system","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128837"}}